Respiratory

Patients with pulmonary arterial hypertension (PAH) received the maximum tolerated dose of background therapy with sotatercept or the placebo to the therapy.

GSK announced its ANCHOR-1 and ANCHOR-2 phase 3 trial results for depemokimab’s efficacy and safety in treating patients with chronic rhinosinusitis with nasal polyps.

The results of this study show that the concurrent presence of asthma and obesity did not synergistically amplify inflammation in children with both asthma and overweight/obesity.

The next-gen molecular Metrix was given emergency use authorization for its ability to test for SARS-CoV-2 and influenza A and B viruses.

The combination includes 2 previously approved vaccines to target the 5 major serogroups of Neisseria meningitidis.

With the acceptance of the new drug application and granting priority review, the target action date is August 12, 2025.

In their exploration of 2 separate respiratory virus seasons, researchers examined the severity of illness for SARS-CoV-2, influenza, and respiratory syncytial virus.

As wildfires ravage Los Angeles County, pharmacists can provide crucial support to their patients.

Patients who receive either Pfizer or GSK’s respiratory syncytial virus vaccine may be at increased risk of Guillain-Barré syndrome.

Researchers compared simultaneous and sequential administration of the mRNA COVID-19 and inactivated influenza vaccines.

Zepbound from Eli Lilly is the first and only prescription medicine approved by the FDA for adults with obstructive sleep apnea and obesity.

Drug Topics met with Lourdes Cross, PharmD, BCACP, CDCES, to discuss pharmacists’ role in managing patients’ chronic obstructive pulmonary disease.

Ruth Carrico, PhD, DNP, APRN, sat down with Drug Topics to discuss the importance of COVID-19 and influenza vaccination.

Women experiencing later menopause may face a heightened risk of asthma, underscoring the possible role of estrogen in the development of the condition.

Pharmacist education can positively impact patient counseling around vaccinations in older adults.

Pharmacist management of chronic conditions can lead to improved patient outcomes.

Three RSV vaccines are currently FDA approved for use in adults aged 60 or older.

On June 26, 2024, the FDA approved ensifentrine (Ohtuvayre) for the treatment of COPD.

Researchers addressed the prevalence of RSV and its associations with immunization, infection, and hospitalization amongst older adults.

Recent research on vitamin D supplementation and respiratory tract infections can help guide pharmacists in counseling patients.

GSK’s respiratory syncytial virus vaccine continued to provide adults aged 60 years and older with clinically meaningful protection.

This year’s annual meeting of the American College of Chest Physicians featured more than 300 educational sessions, insights from over 600 faculty members, and 29.5 hours of CE credits.

Two posters presented at the annual meeting of the American College of Chest Physicians, CHEST 2024, offered insights into the accurate diagnosis and appropriate treatment of ACOS.

Research Presented at CHEST 2024 reported on how mepolizumab can improve asthma control, and reduce exacerbations of concurrent asthma and COPD.

The Healgen Rapid Check COVID-19/Flu A&B Antigen Test is the first at-home test to be granted marketing authorization using a traditional premarket review pathway.

Research presented at CHEST 2024 examined the effect of steroid choice on individuals who have a dual diagnosis of heart failure and COPD.

Research being presented at CHEST 2024 analyzed morbidity and outcomes of children infected with influenza, COVID-19 or both.

The company will be presenting the full BATURA study data as a late-breaker oral presentation at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting.

This year’s meeting will take place from October 6 to 9 in Boston, Massachusetts.

Investigators suggested that the future cost-effectiveness of respiratory syncytial virus (RSV) vaccination could be improved through lower vaccine prices and longer-lasting protection.